Baird Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $240
Baird analyst Mike Polark initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $240.
10 Biggest Price Target Changes For Monday
SVB Leerink raised Natera, Inc. (NASDAQ: NTRA) price target from $140 to $160. Natera shares fell 0.4% to close at $102.88 on Friday.
Needham Maintains Buy on ResMed, Raises Price Target to $267
Needham analyst Mike Matson maintains ResMed (NYSE:RMD) with a Buy and raises the price target from $229 to $267.
Stocks That Hit 52-Week Highs On Friday
Friday's morning session saw 39 companies set new 52-week highs.
5 Reasons Why ResMed Gets Downgrade From BofA Securities
Although ResMed Inc’s (NYSE: RMD) long-term outlook is positive, the market seems to have over-reacted to rival Koninklijke Philips NV’s (NYSE: PHG) recall notification of certain sleep and respiratory care devices for the U.S., according to B
B of A Securities Downgrades ResMed to Underperform, Raises Price Target to $221
B of A Securities analyst Lyanne Harrison downgrades ResMed (NYSE:RMD) from Neutral to Underperform and raises the price target from $216 to $221.
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 15)
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs.